Pulmonx(LUNG) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total worldwide revenue in Q4 2025 was $22.6 million, a 5% decrease from $23.8 million in the same period last year, and a decrease of 7% on a constant currency basis [20] - Worldwide revenue for the full year 2025 was $90.5 million, an 8% increase over the prior year, and a 7% increase on a constant currency basis [20] - Gross margin for Q4 2025 was 77.6%, compared to 74% in the prior year, driven primarily by a lower mix of distributor sales in international markets [23] - Net loss for Q4 2025 was $10.4 million, or a loss of $0.25 per share, compared to a net loss of $13.2 million, or a loss of $0.33 per share for the same period last year [25] - The company expects to significantly decrease its annual cash burn from $32 million in 2025 to $23 million in 2026, representing a reduction of nearly 30% [19] Business Line Data and Key Metrics Changes - U.S. revenue in Q4 was $14.1 million, an 11% decrease from $15.9 million during the same period of the prior year [20] - U.S. revenue for the full year 2025 was $57 million, a 1% increase over the prior year [21] - International revenue in Q4 2025 was $8.5 million, an 8% increase from $7.9 million during the same period last year [22] - International revenue for the full year 2025 was $33.5 million, an increase of 23% over the prior year [22] Market Data and Key Metrics Changes - International growth was driven by continued strength in major European markets, offset by a lack of sales to the distributor in China [22] - The company expects to resume shipments to China in the back half of 2026, following the renewal of its Chinese registration certificate [22][26] Company Strategy and Development Direction - The company has identified three top priorities: re-accelerating U.S. sales growth, advancing clinical initiatives to expand total addressable market (TAM), and aligning spending to achieve financial leverage [7] - AeriSeal program is a key focus, with expectations to grow the total addressable market by an estimated 20% globally upon completion of the CONVERT II trial in 2027 [15][16] - The company is committed to demonstrating meaningful operating leverage and reducing cash burn starting in 2026 [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the underperformance in U.S. revenue was largely due to internal operational challenges and a need for better alignment within the sales organization [8][9] - The company expects U.S. sales growth to resume in the back half of 2026, driven by a refocused commercial strategy and filled sales positions [14][26] - Management remains confident in the business fundamentals and is focused on rebuilding momentum through a clear operating plan [28] Other Important Information - The company executed a cost restructuring initiative that reduced ongoing operating expenses by over 10% [18] - The company closed on a $60 million credit facility, extending the maturity of existing debt to 2031 and providing access to additional capital [18] Q&A Session Summary Question: What percentage of the sales force turned over in Q4? - Management indicated that turnover was across the entire year, with approximately half of the sales organization experiencing turnover [30] Question: How are sales incentives structured now? - The company has made changes to the compensation plan and quota allocation to ensure better alignment and motivation for the sales force [32][34] Question: Why wouldn't growth return sooner with the new sales force in place? - Management noted that the sales team is coming up to speed and that the company is starting from a lower base due to previous declines [40] Question: What specific changes contributed to the 10% cost reduction? - The majority of cost reductions came from G&A and marketing, while ensuring continued investment in key growth areas [44] Question: How is the AeriSeal program being balanced with U.S. sales organization investments? - Management emphasized that the AeriSeal program is a priority, and they are ensuring alignment within the sales organization to support its success [48][50] Question: What is the expected contribution from Japan and China in 2026? - Japan is expected to contribute through revenue-generating patients in a post-approval study, while China sales are anticipated to resume in the back half of 2026 [72][76]